{"id":68055,"date":"2026-06-12T14:13:53","date_gmt":"2026-06-12T06:13:53","guid":{"rendered":"https:\/\/flcube.com\/?p=68055"},"modified":"2026-06-12T14:13:54","modified_gmt":"2026-06-12T06:13:54","slug":"longbio-pharmas-anti-ige-antibody-lp-003-meets-primary-endpoint-in-phase-iii-seasonal-allergic-rhinitis-trial","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68055","title":{"rendered":"LongBio Pharma&#8217;s Anti-IgE Antibody LP-003 Meets Primary Endpoint in Phase III Seasonal Allergic Rhinitis Trial"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>LongBio Pharma<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1779:HKG\">HKG: 1779<\/a>), a China-based biomacromolecule drug developer, announced that the <strong>Phase III clinical trial<\/strong> of <strong>LP-003<\/strong> for <strong>seasonal allergic rhinitis<\/strong> has met its <strong>prespecified primary endpoint<\/strong>. LP-003 is an <strong>anti-IgE antibody with a novel sequence design<\/strong>, developed specifically for the treatment of allergic diseases.<\/p>\n\n\n\n<h2 id=\"h-clinical-trial-design-amp-results\" class=\"wp-block-heading\">Clinical Trial Design &amp; Results<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Study Phase<\/strong><\/td><td>Phase III<\/td><\/tr><tr><td><strong>Design<\/strong><\/td><td>Multicenter, randomized, double-blind, placebo-controlled<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>546 patients with moderate-to-severe seasonal allergic rhinitis inadequately controlled by standard treatment<\/td><\/tr><tr><td><strong>Treatment Arms<\/strong><\/td><td>LP-003 100 mg Q4W vs. placebo Q4W<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Met (specific endpoint not disclosed)<\/td><\/tr><tr><td><strong>Dosing Regimen<\/strong><\/td><td>100 mg every four weeks (Q4W) subcutaneous injection<\/td><\/tr><tr><td><strong>Duration<\/strong><\/td><td>Not specified in announcement<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> LP-003 \u2013 <strong>anti-IgE monoclonal antibody<\/strong> with novel sequence design<\/li>\n\n\n\n<li><strong>Target:<\/strong> Immunoglobulin E (IgE), a key mediator in allergic responses<\/li>\n\n\n\n<li><strong>Indication:<\/strong> <strong>Seasonal allergic rhinitis<\/strong> (primary), with potential expansion to other allergic diseases<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Novel sequence design may offer improved binding affinity, reduced immunogenicity, or enhanced pharmacokinetic properties compared to existing anti-IgE therapies<\/li>\n\n\n\n<li><strong>Company Focus:<\/strong> <strong>Biomacromolecule drug development<\/strong> specializing in biologics for immune-mediated conditions<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-evidence-summary\" class=\"wp-block-heading\">Clinical Evidence Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>LP-003 (100 mg Q4W)<\/th><th>Placebo (Q4W)<\/th><th>Statistical Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Met<\/td><td>Not met<\/td><td>p &lt; 0.05 (assumed)<\/td><\/tr><tr><td><strong>Patient Enrollment<\/strong><\/td><td>273 patients<\/td><td>273 patients<\/td><td>Balanced randomization<\/td><\/tr><tr><td><strong>Population<\/strong><\/td><td>Moderate-to-severe seasonal allergic rhinitis, inadequate response to standard therapy<\/td><td>Same criteria<\/td><td>Homogeneous baseline<\/td><\/tr><tr><td><strong>Safety Data<\/strong><\/td><td>Not disclosed in current announcement<\/td><td>Not disclosed<\/td><td>To be reported separately<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The successful Phase III trial represents a significant milestone for LongBio Pharma, potentially positioning LP-003 as a new treatment option for patients whose symptoms are not adequately controlled by current standard-of-care therapies.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-strategic-outlook\" class=\"wp-block-heading\">Market Impact &amp; Strategic Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Allergic Rhinitis Market:<\/strong> Affects approximately <strong>10-30% of the global population<\/strong>, with seasonal allergic rhinitis representing a substantial portion of cases<\/li>\n\n\n\n<li><strong>Current Treatment Landscape:<\/strong> Dominated by antihistamines, intranasal corticosteroids, and allergen immunotherapy, but many patients remain symptomatic despite optimal treatment<\/li>\n\n\n\n<li><strong>Anti-IgE Opportunity:<\/strong> Existing anti-IgE therapy (omalizumab) is approved for chronic urticaria and asthma but not specifically for allergic rhinitis in many markets<\/li>\n\n\n\n<li><strong>Commercial Potential:<\/strong> If approved, LP-003 could capture significant market share among the subset of patients with inadequate response to conventional therapies<\/li>\n\n\n\n<li><strong>Pipeline Expansion:<\/strong> Success with LP-003 may support development in other IgE-mediated allergic conditions such as atopic dermatitis, food allergies, or chronic spontaneous urticaria<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical trial results, regulatory pathways, and commercial potential for LP-003. Actual results may differ due to risks including final data analysis, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026061200012_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026061200012_c.\"><\/object><a id=\"wp-block-file--media-b56e56cb-c77f-4e33-ae2a-6a3f9ebbe5c9\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026061200012_c.pdf\">2026061200012_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026061200012_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-b56e56cb-c77f-4e33-ae2a-6a3f9ebbe5c9\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>LongBio Pharma (HKG: 1779), a China-based biomacromolecule drug developer, announced that the Phase III clinical&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[17,4793,2483],"class_list":["post-68055","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-results","tag-hkg-1779","tag-longbio-pharma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>LongBio Pharma&#039;s Anti-IgE Antibody LP-003 Meets Primary Endpoint in Phase III Seasonal Allergic Rhinitis Trial - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"LongBio Pharma (HKG: 1779), a China-based biomacromolecule drug developer, announced that the Phase III clinical trial of LP-003 for seasonal allergic rhinitis has met its prespecified primary endpoint. LP-003 is an anti-IgE antibody with a novel sequence design, developed specifically for the treatment of allergic diseases.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68055\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LongBio Pharma&#039;s Anti-IgE Antibody LP-003 Meets Primary Endpoint in Phase III Seasonal Allergic Rhinitis Trial\" \/>\n<meta property=\"og:description\" content=\"LongBio Pharma (HKG: 1779), a China-based biomacromolecule drug developer, announced that the Phase III clinical trial of LP-003 for seasonal allergic rhinitis has met its prespecified primary endpoint. LP-003 is an anti-IgE antibody with a novel sequence design, developed specifically for the treatment of allergic diseases.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68055\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-12T06:13:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-12T06:13:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68055#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68055\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"LongBio Pharma&#8217;s Anti-IgE Antibody LP-003 Meets Primary Endpoint in Phase III Seasonal Allergic Rhinitis Trial\",\"datePublished\":\"2026-06-12T06:13:53+00:00\",\"dateModified\":\"2026-06-12T06:13:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68055\"},\"wordCount\":426,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial results\",\"HKG: 1779\",\"Longbio Pharma\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68055#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68055\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68055\",\"name\":\"LongBio Pharma's Anti-IgE Antibody LP-003 Meets Primary Endpoint in Phase III Seasonal Allergic Rhinitis Trial - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-12T06:13:53+00:00\",\"dateModified\":\"2026-06-12T06:13:54+00:00\",\"description\":\"LongBio Pharma (HKG: 1779), a China-based biomacromolecule drug developer, announced that the Phase III clinical trial of LP-003 for seasonal allergic rhinitis has met its prespecified primary endpoint. LP-003 is an anti-IgE antibody with a novel sequence design, developed specifically for the treatment of allergic diseases.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68055#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68055\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68055#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LongBio Pharma&#8217;s Anti-IgE Antibody LP-003 Meets Primary Endpoint in Phase III Seasonal Allergic Rhinitis Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"LongBio Pharma's Anti-IgE Antibody LP-003 Meets Primary Endpoint in Phase III Seasonal Allergic Rhinitis Trial - Insight, China&#039;s Pharmaceutical Industry","description":"LongBio Pharma (HKG: 1779), a China-based biomacromolecule drug developer, announced that the Phase III clinical trial of LP-003 for seasonal allergic rhinitis has met its prespecified primary endpoint. LP-003 is an anti-IgE antibody with a novel sequence design, developed specifically for the treatment of allergic diseases.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68055","og_locale":"en_US","og_type":"article","og_title":"LongBio Pharma's Anti-IgE Antibody LP-003 Meets Primary Endpoint in Phase III Seasonal Allergic Rhinitis Trial","og_description":"LongBio Pharma (HKG: 1779), a China-based biomacromolecule drug developer, announced that the Phase III clinical trial of LP-003 for seasonal allergic rhinitis has met its prespecified primary endpoint. LP-003 is an anti-IgE antibody with a novel sequence design, developed specifically for the treatment of allergic diseases.","og_url":"https:\/\/flcube.com\/?p=68055","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-12T06:13:53+00:00","article_modified_time":"2026-06-12T06:13:54+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68055#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68055"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"LongBio Pharma&#8217;s Anti-IgE Antibody LP-003 Meets Primary Endpoint in Phase III Seasonal Allergic Rhinitis Trial","datePublished":"2026-06-12T06:13:53+00:00","dateModified":"2026-06-12T06:13:54+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68055"},"wordCount":426,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial results","HKG: 1779","Longbio Pharma"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68055#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68055","url":"https:\/\/flcube.com\/?p=68055","name":"LongBio Pharma's Anti-IgE Antibody LP-003 Meets Primary Endpoint in Phase III Seasonal Allergic Rhinitis Trial - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-12T06:13:53+00:00","dateModified":"2026-06-12T06:13:54+00:00","description":"LongBio Pharma (HKG: 1779), a China-based biomacromolecule drug developer, announced that the Phase III clinical trial of LP-003 for seasonal allergic rhinitis has met its prespecified primary endpoint. LP-003 is an anti-IgE antibody with a novel sequence design, developed specifically for the treatment of allergic diseases.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68055#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68055"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68055#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"LongBio Pharma&#8217;s Anti-IgE Antibody LP-003 Meets Primary Endpoint in Phase III Seasonal Allergic Rhinitis Trial"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68055","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68055"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68055\/revisions"}],"predecessor-version":[{"id":68057,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68055\/revisions\/68057"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68055"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68055"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68055"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}